Drugs / Ultibro
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02813200 | Jan 2017 → Feb 2019 | chronic obstructive pulmonary disease | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03527927 | May 2017 → Aug 2019 | chronic obstructive pulmonary disease | Hywel Dda Health Board | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02579850 Comparator | May 2015 → Jul 2017 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | Met primary |
| Phase 4 | NCT06282861 Comparator | Feb 2024 → Jan 2025 | chronic obstructive pulmonary disease | Fundacio Privada Mon Clinic Barcelona | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultibro | “The participants will choose: Ultibro® (Breezhaler device) or Duaklir® (Genuair device) or Anoro® (Ellipta device) or Spiolto® (Respimat device) and they will be prescribed the...” NCT03527927 ↗ |
| Modality | Other / unclassified | “a single-inhaler dual bronchodilator combination of indacaterol plus glycopyrronium (IND/GLY)” PMID 29429593 ↗ Feb 2018 |
| Route | Inhaled | “administered once daily via DPI” NCT02579850 ↗ |